Answer of the Week · #26

One stage. One question. One answer.

Week 26 · 2026· Reference: Selina Gärtner Consulting· Global Pharma Tech Summit 2026, London

Four weeks ago, Selina Gärtner opened the Global Pharma Tech Summit 2026 in London. 24 minutes, 125 senior leaders from pharma and life sciences, one central question: what does Stage-3 AI actually look like in pharma commercial? She showed the answer live, on stage — Maria. As of this week, it's official: Selina is a TÜV Rheinland-certified Frag-Maria™ partner for Pharma & Life Sciences. And on her own website, Maria hasn't been answering demo questions for a while now — she's answering real ones.

125
Senior leaders from pharma & life sciences watched for two minutes as Maria showed four things a Stage-2 tool can't do.
M
Frag-Maria™ at Selina Gärtner Consulting● Online · Pharma & Life Sciences
🔒 Privacy agent confirmed — consent given, session active
Round 1 · First contact
Where should I start with AI?
That depends on where you're standing right now — and what you want to achieve. Where does AI cost you the most time or uncertainty today? Is it strategy, implementation, or simply the question of where to begin?
Round 2 · Clarification
I don't really know everything you can do with it.
I see — then it makes sense to first clarify what's actually relevant in your area. Selina built a short AI-readiness scorecard for exactly that — 5 minutes, a concrete read on where you stand and where the biggest levers are. Built specifically for life-science teams. Interested, or should I first outline where AI actually makes a difference in commercial teams today?
Round 3 · Deep dive
Interesting.
Good — here's the short version: Sales & KAM — prepping for HCP conversations, institutional memory, post-call documentation without typing a word. Medical Affairs — literature research in minutes instead of days, compliance-checked answers, MSL briefings. Marketing — content, presentations, campaign prep, without starting from zero. The key point: AI only works when it's built into existing processes — not as a standalone tool on the side.
Round 4 · Wrap-up
Where can I find this score?
Here's the link — about 5 minutes, a concrete read on where you stand: ➡️ Go to the scorecard. If you still have questions afterward, or want to talk to Selina directly, just let me know.

What's actually happening here

This isn't an FAQ bot rehashing product sheets. In four sentences, Maria turns a vague intent — “Where should I start?” — into one concrete next action: the scorecard. She doesn't promise anything she can't deliver, and she doesn't make medical or regulatory judgment calls that actually belong to Selina. This is exactly the architecture Selina showed three weeks earlier in London — four things a Stage-2 tool can't do:

1
Educates
With the reasoning built into the answer itself — not just a fact, but the why behind it.
2
Restricts
A refusal that points to the actual regulatory boundary — not a shrug.
3
Redirects
The human stays in the lead. That's not a bug, that's the design.
4
Resolves
CRM entry, follow-up draft — the admin layer that otherwise drives reps to shadow tools.
Not Copilot with a corporate license. Not ChatGPT with a disclaimer. An agent built on a regulatory architecture — from day one.
When Maria doesn't answer

In London, one CIO told Selina that hundreds of unsanctioned AI tools are running in their commercial org — “and we pretend we don't.” A Head of Medical Affairs asked how to move her MSLs from ChatGPT to something they can actually audit. That's exactly what the three-step escalation gate is built for: Maria doesn't give advice when she's uncertain. She confirms the request, captures contact details — and only then hands it off, documented, to a human.

What this means for regulated industries

Pharma is the extreme case — but the pattern holds for any regulated SME. Whoever doesn't provide vetted AI today will get unvetted AI through the back door tomorrow. The question is no longer whether a team uses AI, but who builds the architecture for it — and who will be retrofitting it in two years. Selina brings the pharma depth, Frag-Maria™ the architecture behind it.

Shadow AIEU AI Act · High RiskAudit TrailMSL EnablementCompliance by Design
The next 90 days will decide who builds governance — and who's retrofitting it in two years. The window for the EU AI Act's high-risk obligations is closing.
Want to experience Maria yourself, or talk through implementation for your team? Two doors, one starting point.
Book a Use Case Scan
0 commentson Selina Gaertner. Three dimensions. A clear profile.